Cargando…

Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis

Anti-PD-1/PD-L1 antibodies are widely used in anti-cancer therapy. While they have improved cancer prognoses, immune-related adverse events, which can cause acute kidney injury (AKI), cannot be ignored. The purpose of this retrospective cohort study was to assess the incidence, risk factors, and pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lou, Qianqian, Gong, Jianguang, Ye, Binxian, Yu, Rizhen, Bu, Shuangshan, Li, Yiwen, Zhu, Bin, Shao, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373620/
https://www.ncbi.nlm.nih.gov/pubmed/37491871
http://dx.doi.org/10.1080/0886022X.2023.2238823
_version_ 1785078602704879616
author Lou, Qianqian
Gong, Jianguang
Ye, Binxian
Yu, Rizhen
Bu, Shuangshan
Li, Yiwen
Zhu, Bin
Shao, Lina
author_facet Lou, Qianqian
Gong, Jianguang
Ye, Binxian
Yu, Rizhen
Bu, Shuangshan
Li, Yiwen
Zhu, Bin
Shao, Lina
author_sort Lou, Qianqian
collection PubMed
description Anti-PD-1/PD-L1 antibodies are widely used in anti-cancer therapy. While they have improved cancer prognoses, immune-related adverse events, which can cause acute kidney injury (AKI), cannot be ignored. The purpose of this retrospective cohort study was to assess the incidence, risk factors, and prognosis of AKI associated with anti-PD-1/PD-L1 antibodies. Patients who received anti-PD-1/PD-L1 antibody treatment at our hospital between January 2018 and December 2022 were enrolled. Clinical information, combined medications, concomitant diseases, tumor types, and laboratory indicators were collected from patient records, and the incidence of AKI was determined. The risk factors for AKI were assessed using univariate and multivariate logistic regression analyses. Overall, 1418 patients were enrolled. The median follow-up time was 112 days and 92 (6.5%) developed AKI. The median time from the initial anti-PD-1/PD-L1 antibody treatment to AKI was 99.85 days. Head and neck cancer and combined use of diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), lower hemoglobin level, and other types of chemotherapeutic drugs were independent risk factors for AKI. The complete recovery, partial recovery, non-recovery, and unknown AKI rates were 7.6%, 28.3%, 52.2%, and 11.9%, respectively. Kidney biopsies were performed on two patients with AKI and pathology confirmed diagnosis of acute tubulointerstitial nephritis. In this cohort, AKI was not uncommon in patients treated with anti-PD-1/PD-L1 antibodies; therefore, it is necessary to monitor renal function and identify AKI early, especially in patients with head and neck tumors. Improving anemia and minimizing the use of diuretics, NSAIDs, and chemotherapeutics may reduce AKI.
format Online
Article
Text
id pubmed-10373620
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-103736202023-07-28 Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis Lou, Qianqian Gong, Jianguang Ye, Binxian Yu, Rizhen Bu, Shuangshan Li, Yiwen Zhu, Bin Shao, Lina Ren Fail Research Article Anti-PD-1/PD-L1 antibodies are widely used in anti-cancer therapy. While they have improved cancer prognoses, immune-related adverse events, which can cause acute kidney injury (AKI), cannot be ignored. The purpose of this retrospective cohort study was to assess the incidence, risk factors, and prognosis of AKI associated with anti-PD-1/PD-L1 antibodies. Patients who received anti-PD-1/PD-L1 antibody treatment at our hospital between January 2018 and December 2022 were enrolled. Clinical information, combined medications, concomitant diseases, tumor types, and laboratory indicators were collected from patient records, and the incidence of AKI was determined. The risk factors for AKI were assessed using univariate and multivariate logistic regression analyses. Overall, 1418 patients were enrolled. The median follow-up time was 112 days and 92 (6.5%) developed AKI. The median time from the initial anti-PD-1/PD-L1 antibody treatment to AKI was 99.85 days. Head and neck cancer and combined use of diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), lower hemoglobin level, and other types of chemotherapeutic drugs were independent risk factors for AKI. The complete recovery, partial recovery, non-recovery, and unknown AKI rates were 7.6%, 28.3%, 52.2%, and 11.9%, respectively. Kidney biopsies were performed on two patients with AKI and pathology confirmed diagnosis of acute tubulointerstitial nephritis. In this cohort, AKI was not uncommon in patients treated with anti-PD-1/PD-L1 antibodies; therefore, it is necessary to monitor renal function and identify AKI early, especially in patients with head and neck tumors. Improving anemia and minimizing the use of diuretics, NSAIDs, and chemotherapeutics may reduce AKI. Taylor & Francis 2023-07-25 /pmc/articles/PMC10373620/ /pubmed/37491871 http://dx.doi.org/10.1080/0886022X.2023.2238823 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Research Article
Lou, Qianqian
Gong, Jianguang
Ye, Binxian
Yu, Rizhen
Bu, Shuangshan
Li, Yiwen
Zhu, Bin
Shao, Lina
Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis
title Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis
title_full Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis
title_fullStr Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis
title_full_unstemmed Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis
title_short Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis
title_sort acute kidney injury in patients with cancer receiving anti-pd-1/pd-l1 antibodies: incidence, risk factors, and prognosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373620/
https://www.ncbi.nlm.nih.gov/pubmed/37491871
http://dx.doi.org/10.1080/0886022X.2023.2238823
work_keys_str_mv AT louqianqian acutekidneyinjuryinpatientswithcancerreceivingantipd1pdl1antibodiesincidenceriskfactorsandprognosis
AT gongjianguang acutekidneyinjuryinpatientswithcancerreceivingantipd1pdl1antibodiesincidenceriskfactorsandprognosis
AT yebinxian acutekidneyinjuryinpatientswithcancerreceivingantipd1pdl1antibodiesincidenceriskfactorsandprognosis
AT yurizhen acutekidneyinjuryinpatientswithcancerreceivingantipd1pdl1antibodiesincidenceriskfactorsandprognosis
AT bushuangshan acutekidneyinjuryinpatientswithcancerreceivingantipd1pdl1antibodiesincidenceriskfactorsandprognosis
AT liyiwen acutekidneyinjuryinpatientswithcancerreceivingantipd1pdl1antibodiesincidenceriskfactorsandprognosis
AT zhubin acutekidneyinjuryinpatientswithcancerreceivingantipd1pdl1antibodiesincidenceriskfactorsandprognosis
AT shaolina acutekidneyinjuryinpatientswithcancerreceivingantipd1pdl1antibodiesincidenceriskfactorsandprognosis